Horseshoes, Hand Grenades, and Body-Surface Area–Based Dosing: Aiming for a Target-Reference-Cited by-同舟云学术

Horseshoes, Hand Grenades, and Body-Surface Area–Based Dosing: Aiming for a Target

Published:2003-01-15 Issue:2 Volume:21 Page:182-183
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Egorin Merrill J.¹

Affiliation:

1. University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.10.084

Reference7 articles.

1. Animal scale-up

2. Freireich EJ, Gehan EA, Rall DP, et al: Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey, and man. Cancer Chemother Rep 50:219,1966–244,

3. Is Dose Normalization to Weight or Body Surface Area Useful in Adults?

4. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile?

5. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13

2. Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework;Expert Opinion on Drug Delivery;2023-02-28

3. Customer-centric product presentations for monoclonal antibodies;AAPS Open;2023-01-23

4. Enabling customer-centric and sustainable drug delivery— formulation and device lifecycle management of biotherapeutics;Formulation and Device Lifecycle Management of Biotherapeutics;2022

5. Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach;Formulation and Device Lifecycle Management of Biotherapeutics;2022